

November 1, 2023

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division (TEL: 81-3-6838-2803)

Notice Regarding Approval of Partial Amendments to Dosage and Administration of
Famciclovir Tablets 250mg “KYOSOMIRAI” and
Famciclovir Tablets 250mg “KMP” for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, received an approval of partial amendments to dosage and administration of Famciclovir Tablets 250mg “KYOSOMIRAI” and Famciclovir Tablets 250mg “KMP” on November 1, 2023 as below.

Outline of Famciclovir Tablets 250mg “KYOSOMIRAI” and Famciclovir Tablets 250mg “KMP”

Class	Product Name	Original Brand Name
Anti-herpesvirus agents	Famciclovir Tablets 250mg “KYOSOMIRAI” Famciclovir Tablets 250mg “KMP”	Famvir ®Tablets 250mg

Outline of Amendments to Dosage and Administration of Famciclovir Tablets 250mg “KYOSOMIRAI” and Famciclovir Tablets 250mg “KMP”

Indications and Usage	Dosage and Administration
Herpes simplex	The usual adult dosage is 250 mg of famciclovir administered orally three times daily. <u>In addition, in the case of recurrent herpes simplex, famciclovir 1000 mg orally two times can usually be given to adults.</u>
Herpes zoster	The usual adult dosage is 500 mg of famciclovir administered orally three times daily.

(Underlined parts are revised parts.)